ライフサイエンスコーパス: muscle spasm

1 sponsible for the crotamine-induced skeletal muscle spasm.

2 SCI restoration of neuronal excitability and muscle spasms.

3 mished by maladaptive changes that can cause muscle spasms.

4 5.9%), falls (22.2%), headaches (20.4%), and muscle spasms (11.1%).

5 drug-related adverse effects, most commonly muscle spasms (12 patients), weight loss (10), dysgeusia

6 y, patients receiving etelcalcetide had more muscle spasms (12.0% and 11.1% vs 7.1% and 6.2% with pla

7 differences between arms (PAG v AG) included muscle spasms (13% v 1%), neutropenia (29% v 18%), and m

8 ients), hypertension (22 [12%] vs six [3%]), muscle spasms (22 [12%] vs seven [4%]), acne (20 [11%] v

9 e events reported with teprotumumab included muscle spasms (25%), nausea (17%), alopecia (13%), diarr

10 se events (AEs) of diarrhea (34.7% v 22.8%), muscle spasms (28.6% v 11.9%), hypertension (25.5% v 14.

11 in 491 (98%) patients; the most common were muscle spasms (317 [64%]), alopecia (307 [62%]), dysgeus

12 reported adverse events with bimagrumab were muscle spasms (32 [51%] in the bimagrumab 10 mg/kg group

13 ents of any grade were diarrhoea (48 [66%]), muscle spasms (45 [62%]), and fatigue (41 [56%]).

14 most common grade 1 or 2 complications were muscle spasm (76%), followed by dysgeusia (57%), alopeci

15 adelpar 50 mg and one on seladelpar 200 mg), muscle spasms (8%; three patients on seladelpar 200 mg),

16 is characterised by progressive rigidity and muscle spasms affecting the axial and limb muscles.

17 ons, opening up new targets for treatment of muscle spasms after SCI.

18 nes are used for treating anxiety, epilepsy, muscle spasm, alcohol withdrawal, palliation, insomnia,

19 occurring in more than 30% of patients were muscle spasms, alopecia, dysgeusia (taste disturbance),

20 CT scanning to minimize the degree of smooth-muscle spasm and peristalsis and to reduce the patient's

21 ctomy would create a prolonged inhibition of muscle spasm and postoperative pain, facilitating tissue

22 g/kg per day [0.0-14.8]; p=0.005) to control muscle spasms and associated tachycardia.

23 chanical ventilation and improves control of muscle spasms and autonomic instability.

24 m Clostridium tetani and is characterised by muscle spasms and autonomic nervous system dysfunction.

25 assisted ventilation and of drugs to control muscle spasms and cardiovascular instability within the

26 e the requirement for other drugs to control muscle spasms and cardiovascular instability.

27 the patient exhibits unusual signs, such as muscle spasms and fever.

28 ions of cannabis in the treatment of painful muscle spasms and other symptoms of multiple sclerosis a

29 3-20 Hz correlated with the strength of the muscle spasms and preceded them by approximately 320 ms.

30 use/facial muscles, migraine/facial and head muscles, spasms and spasticity/upper and lower limbs, to

31 ith fatigue, two with hyponatremia, one with muscle spasm, and one with atrial fibrillation.

32 hralgia, urinary tract infection, back pain, muscle spasms, and dyspepsia were higher with ibrutinib,

33 tients were back pain, arthralgia, headache, muscle spasms, and pain in extremity (all <2%).

34 ion, diarrhea, peripheral edema, hemorrhage, muscle spasms, and pneumonia, as well as adverse events

35 Muscle spasms are common in chronic spinal cord injury (

36 In addition, acute muscle spasms associated with oxaliplatin were significa

37 s also useful for treatment of spasticity or muscle spasms associated with several clinical condition

38 worse treatment-related adverse events were muscle spasms (four [4%] patients in treatment group A v

39 aemia, and strokes with anastrozole and more muscle spasm, gynaecological cancers and symptoms, vasom

40 s characterized by muscle rigidity, episodic muscle spasms, high titers of antibodies against glutami

41 clonus is characterized by rigidity, painful muscle spasms, hyperekplexia, and brainstem signs.

42 e as free doxorubicin injections in reducing muscle spasms in blepharospasm patients but with increas

43 ion, anxiety, mood swings, severe headaches, muscle spasms, interphalangeal joint stiffness, decrease

44 isease flare (n = 2), hyperglycemia (n = 1), muscle spasms (n = 1), and multiple AEs (n = 8).

45 ommon adverse events were fatigue, diarrhea, muscle spasms, nausea, and bruising.

46 pulse generator pocket pain (five [4%]), and muscle spasm or cramp (three [2%]).

47 hototherapeutic applications to safely treat muscle spasms, pain, anxiety, sleep disorders, and epile

48 s in the placebo group), with hypocalcaemia, muscle spasm, paraesthesias, headache, and nausea being

49 s (muscle stiffness, pain and discomfort and muscle spasms,), physical impact (activities of daily li

50 the number of injections needed for patient muscle spasm relief, decreasing the risk of negative sid

51 f baclofen on spasticity (e.g. management of muscle spasms that may otherwise hinder movement or soci

52 Muscle spasms, the most frequent adverse event in the ba

53 ith uncontrolled falls, and episodic painful muscle spasms triggered by anxiety, task-specific phobia

54 Dystonic involuntary muscle spasms were specifically associated with increase

55 the neurons in the lumbar spinal cord led to muscle spasms without meaningful locomotion.